Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Passaro A, et al. Among authors: shah s. Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879444 Free article. Clinical Trial.
Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer.
Noronha V, Prabhash K, Joshi A, Patil VM, Talole S, Nakti D, Sahu A, Shah S, Ghosh-Laskar S, Patil PS, Mehta SA, Jambhekar N, Mahajan A, Purandare N. Noronha V, et al. Among authors: shah s. Oncol Res. 2016;23(4):183-95. doi: 10.3727/096504016X14537290676865. Oncol Res. 2016. PMID: 27053347 Free PMC article.
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Noronha V, et al. Among authors: shah s. J Clin Oncol. 2020 Jan 10;38(2):124-136. doi: 10.1200/JCO.19.01154. Epub 2019 Aug 14. J Clin Oncol. 2020. PMID: 31411950 Clinical Trial.
Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
Behel V, Chougule A, Noronha V, Patil VM, Menon N, Singh A, Chopade S, Kumar R, Shah S, More S, Banavali SD, Chandrani P, Prabhash K. Behel V, et al. Among authors: shah s. Clin Lung Cancer. 2022 Jul;23(5):410-418. doi: 10.1016/j.cllc.2022.04.002. Epub 2022 Apr 30. Clin Lung Cancer. 2022. PMID: 35649817
Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study.
Noronha V, Patil V, Menon N, Kalra D, Singh A, Shah M, Goud S, Jobanputra K, Nawale K, Shah S, Chowdhury OR, Mathrudev V, Jogdhankar S, Singh MY, Singh A, Adak S, Sandesh M, Arunkumar R, Kumar S, Mahajan A, Prabhash K. Noronha V, et al. Among authors: shah s, shah m. Med Oncol. 2023 Dec 21;41(1):26. doi: 10.1007/s12032-023-02234-z. Med Oncol. 2023. PMID: 38129716 Clinical Trial.
A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC.
Noronha V, Menon NS, Patil VM, Chandrakanth MV, More S, Dhanawat A, Chowdhary OR, Singh AC, Goud S, Shah S, Karuvandan N, Jobanputra KN, Shah DK, Shah MJ, Sarma R, Patel D, Joarder R, Kumar P, John A, Kaur J, Bagra S, Purandare N, Janu A, Mahajan A, Prabhash K. Noronha V, et al. Among authors: shah dk, shah mj, shah s. JTO Clin Res Rep. 2023 Dec 18;5(1):100622. doi: 10.1016/j.jtocrr.2023.100622. eCollection 2024 Jan. JTO Clin Res Rep. 2023. PMID: 38292414 Free PMC article.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Butts C, et al. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. Lancet Oncol. 2014. PMID: 24331154 Free article. Clinical Trial.
Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial.
Noronha V, Bhattacharjee A, Patil VM, Joshi A, Menon N, Shah S, Kannan S, Mukadam SA, Maske K, Ishi S, Prabhash K. Noronha V, et al. Among authors: shah s. Chest. 2020 Jun;157(6):1647-1655. doi: 10.1016/j.chest.2019.11.048. Epub 2020 Jan 18. Chest. 2020. PMID: 31958446 Clinical Trial.
15,469 results
You have reached the last available page of results. Please see the User Guide for more information.